Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Gene therapy for head and neck cancer using vaccinia virus expressing IL-2in a murine model, with evidence of immune suppression
Autore:
Qin, HZ; Valentino, J; Manna, S; Tripathi, PK; Bhattacharya-Chatterjee, M; Foon, KA; OMalley, BW; Chatterjee, SK;
Indirizzi:
Univ Cincinnati, Dept Internal Med, Cincinnati, OH 45267 USA Univ Cincinnati Cincinnati OH USA 45267 nal Med, Cincinnati, OH 45267 USA Univ Cincinnati, Barrett Canc Ctr, Cincinnati, OH 45267 USA Univ Cincinnati Cincinnati OH USA 45267 anc Ctr, Cincinnati, OH 45267 USA Univ Kentucky, Dept Otolaryngol Head & Neck Surg, Lexington, KY 40536 USA Univ Kentucky Lexington KY USA 40536 & Neck Surg, Lexington, KY 40536 USA Univ Maryland, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21201 USA Univ Maryland Baltimore MD USA 21201 & Neck Surg, Baltimore, MD 21201 USA
Titolo Testata:
MOLECULAR THERAPY
fascicolo: 6, volume: 4, anno: 2001,
pagine: 551 - 558
SICI:
1525-0016(200112)4:6<551:GTFHAN>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
SQUAMOUS-CELL CARCINOMA; COLONY-STIMULATING FACTOR; GROWTH-FACTOR-BETA; TUMOR-INFILTRATING LYMPHOCYTES; GM-CSF; NITRIC-OXIDE; ORAL-CANCER; INTERLEUKIN-2; IMMUNOTHERAPY; TUMORIGENICITY;
Keywords:
head and neck squamous cell carcinoma; immune suppression; vaccinia virus; IL-2; tumor vaccine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
46
Recensione:
Indirizzi per estratti:
Indirizzo: Chatterjee, SK Univ Cincinnati, Dept Internal Med, Cincinnati, OH 45267 USA Univ Cincinnati Cincinnati OH USA 45267 nati, OH 45267 USA
Citazione:
H.Z. Qin et al., "Gene therapy for head and neck cancer using vaccinia virus expressing IL-2in a murine model, with evidence of immune suppression", MOL THER, 4(6), 2001, pp. 551-558

Abstract

We evaluated the efficiency of recombinant vaccinia virus expressing interleukin-2 (rvv-IL-2) as a tumor vaccine in an immunocompetent mouse model ofhead and neck squamous cell carcinoma (SCC VII/SF). Mice with five-day-oldtumors in the floor of the mouth were treated with rvv-IL-2 by intratumoral injections. These treated mice survived longer (P <.03) than mice treatedwith control vaccines. Splenocytes, bone marrow, and lymph node cells fromtumor-bearing mice responded poorly to concanavalin A stimulation, suggesting induction of immunosuppression. The rvv-IL-2 virus grew for 7 days in the tumor following intratumoral injection. We did not detect any virus particles in several normal organs following rvv-IL-2 injection. Comparison of expression levels of several potential immune inhibitory mediators between the tumors growing in mice and cultured tumor cells demonstrated higher expression of IL-10, GM-CSF, TGF-<beta>, and NO synthetase in tumors. These results suggested possible roles for these molecules in immunosuppression. Weconclude that rvv-IL-2 has potential as a therapeutic vaccine for head andneck cancer and that it can be more effective provided the immunosuppression is reversed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 07:35:56